Skip to content

Smartphone-based Aftercare for Inpatients With Anorexia Nervosa

Therapist-guided Smartphone-based Aftercare for Inpatients With Severe Anorexia Nervosa (SMART-AN): a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04228939
Acronym
SMART-AN
Enrollment
184
Registered
2020-01-14
Start date
2019-01-01
Completion date
2021-07-31
Last updated
2020-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anorexia Nervosa

Brief summary

Inpatient treatment for patients with anorexia nervosa (AN) is recommended in extreme or severe cases after failure of outpatient treatment and is highly effective. However, a number of patients show symptom increase and relapse after discharge. The aim of this study is to evaluate the efficacy of a guided smartphone-based aftercare intervention following inpatient treatment of patients with AN to support symptom stabilization or continued improvement.

Detailed description

Anorexia nervosa (AN) is a severe, often chronic and life-threatening disorder. Relapse after treatment is common with relapse rates ranging between 9 and 52% and being highest within the first year following treatment particularly as early as 3 months posttreatment. Even if weight restoration is achieved, it is quite difficult for patients to sustain improvements after treatment, so aftercare and relapse prevention are essential research topics. There is a recent review on internet- and mobile-based aftercare and relapse prevention in mental disorders that concludes that there is some evidence that such interventions are feasible instruments for maintaining treatment gains for some mental disorders, including eating disorders (EDs). However, the authors claim for further high quality, large-scale trials that are needed to expand research fields. So, the aim of this study is to prove the efficacy of a guided smartphone-based aftercare intervention for inpatients with AN. Our primary hypothesis is that at the end of aftercare intervention (T1), the intervention group shows a significantly lower eating disorder symptomatology than the control group. Eligible patients with AN who are discharged from inpatient treatment are randomized either to receive a 4-month smartphone-based aftercare intervention with therapist feedback as an add-on element to treatment as usual (TAU) or TAU alone. Assessments include structured interviews as well as online questionnaires and are taken at baseline (discharge, T0), end of the aftercare intervention (T1) as well as 6-month follow-up (T2).

Interventions

Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 4-8, every other week in weeks 8-12 and once in week 16.

BEHAVIORALTreatment as usual (TAU)

Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2.

Sponsors

Schoen Clinic Roseneck
CollaboratorUNKNOWN
Swiss Anorexia Nervosa Foundation
CollaboratorUNKNOWN
Ludwig-Maximilians - University of Munich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
12 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* primary diagnosis of AN (DSM-5: 307.1), * sex: female, * age: from 12 years onwards to 60 years, * regular completion of inpatient treatment, * at least a length of inpatient stay of 6 weeks, * BMI at discharge at least 15, at least a 1-point BMI increase during inpatient treatment, * owner of a smartphone, * informed consent of the patient and, in case of minors, also of the parents.

Exclusion criteria

* major depression (BDI-II \> 29 at discharge), * suicidal tendency (item 9 of BDI-II \> 1 at discharge), * very high level of care after inpatient treatment (e.g. therapeutic living community, day clinic), * pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Changes in Eating Disorder Severity (assessor-based)Measured at baseline (discharge), at week 16 (end of treatment) and 6 month follow-upThe Eating Disorder Examination (EDE) will be used to measure asessor-based eating disorder symptom severity over time.

Secondary

MeasureTime frameDescription
Changes in Eating Disorder Severity (self-report)Measured at baseline, week 16 and 6 month follow-upThe Eating Disorder Examination Questionnaire (EDE-Q) will be used to measure self-reported eating disorder symptom severity over time.
Changes in depressive symptomsMeasured at baseline, week 16 and 6 month follow-upThe Beck Depression Inventory-II (BDI-II) will be used to measure depressive symptoms over time.
Changes in stages of change regarding specific eating disorder behaviorsMeasured at baseline, week 16 and 6 month follow-upThe Stages of Change Questionnaire for Eating Disorders (SOCQ-ED) will be used to measure changes in stages of change regarding specific eating disorder behaviors over time.
Changes in self-efficayMeasured at baseline, week 16 and 6 month follow-upThe General Self-Efficacy Scale (GSE) will be used to measure self-efficacy over time.
Changes in Body-Mass-Index (BMI)Measured at baseline, week 16 and 6 month follow-upWeight and height will be used to measure BMI over time.
Additional outpatient and inpatient treatment after dischargeMeasured at week 16 and 6 month follow-upNumber and length of outpatient or inpatient treatment (rehospitalization) since discharge will be assessed.
Adherence to the smartphone-based aftercare interventionMeasured from baseline to week 16Adherence will be measured via dichotomous outcome of drop-out (individuals will be considered as drop-out if they fail to login to the app at all for a period of 14 consecutive days. Adherence will be assessed through application usage data.
Adherence to self-monitoring tasksMeasured from baseline to week 16Frequency of self-monitoring entries will be tracked automatically through the program server
Participant satisfaction with the app and the aftercare interventionMeasured at week 16A self-developed questionnaire will be used to assess self-reported satisfaction with the app and the aftercare intervention.

Countries

Germany

Contacts

Primary ContactSandra Schlegl, PhD
sandra.schlegl@med.uni-muenchen.de+4989440053369
Backup ContactUlrich Voderholzer, Prof
uvoderholzer@schoen-klinik.de+49 8051 68-100102

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 24, 2026